EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy

Science

Volumn 304, Issue 5676, 2004, Pages 1497-1500

  Paez, J Guillermo ^a,b   Jänne, Pasi A ^a,b   Lee, Jeffrey C ^a,c   Tracy, Sean ^a   Greulich, Heidi ^a,b   Gabriel, Stacey ^d   Herman, Paula ^a   Kaye, Frederic J ^e   Lindeman, Neal ^b   Boggon, Titus J ^a,c   Naoki, Katsuhiko ^a   Sasaki, Hidefumini ^f   Fujii, Yoshitaka ^f   Eck, Michael J ^a,c   Sellers, William R ^a,b,d   Johnson, Bruce E ^a,b   Meyerson, Matthew ^a,c,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; CELLS; DRUG THERAPY; GENES; MUTAGENESIS;

GROWTH INHIBITION; LUNG CANCER; MUTATIONS; TYROSINE KINASE;

TUMORS;

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; GENOMIC DNA; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONCENTRATION RESPONSE; EGFR GENE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXON; FEMALE; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECEPTOR GENE; TREATMENT OUTCOME; VIRUS ONCOGENE;

ADENOCARCINOMA; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CONTROLLED CLINICAL TRIALS; ENZYME INHIBITORS; FEMALE; GENES, ERBB-1; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; MUTATION, MISSENSE; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION; TREATMENT OUTCOME; UNITED STATES;

EID: 2342624080     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1099314     Document Type: Article

References (29)

1. C. L. Sawyers, Genes Dev. 17, 2998 (2003).
2. G. D. Demetri et al., N. Engl. J. Med. 347, 47Z (2002).
3. B. J. Druker et al., N. Engl. J. Med. 344, 1038 (2001).
4. D. J. Slamon et al., N. Engl. J. Med. 344, 783 (2001).
5. H. Davies et al., Nature 417, 949 (2002).
6. A. Bardelli et al., Science 300, 949 (2003).
7. Y. Samuels et al., Science 304, 554 (2004).
8. A. Jemat et al., CA Cancer J. Clin. 54, 8 (2004).
9. O. S. Breathnach et al., J. Clin. Oncol. 19, 1734 (2001).
10. V. Rusch et al., Cancer Res. 53, 2379 (1993).
11. R. Bailey et al., Lung Cancer 41 S2, S71 (2003).
12. H. M. Fukuoka et al., J. Clin. Oncol. 21, 2237 (2003).
13. P. A. Janne et al., Lung Cancer 44, 221 (2004).
14. M. G. Kris et al., JAMA 290, 2149 (2003).
15. V. A. Miller et al., J. Clin. Oncol. 22, 1103 (2004).
16. Materials and methods, additional data tables and figures, and additional references are available as supporting material on Science Online.
17. M. Huse, J. Kuriyan, Cell 109, 275 (2002).
18. K. Naoki., T. H. Chen, W. G. Richards, D. J. Sugarbaker, M. Meyerson, Cancer Res. 62, 7001 (2002).
19. J. Stamos, M. X. Sliwkowski, C. Eigenbrot, J. Biol. Chem. 277, 46265 (2002).
20. -12.
21. T. Fujishita et al., Oncology 64, 399 (2003).
22. M. Ono et al., Mol. Cancer Ther. 3, 465 (2004).
23. M. C. Heinrich et al., J. Clin. Oncol. 21, 4342 (2003).
24. G. Glaccone et al., Clin. Oncol. 22, 777 (2004).
25. R. S. Herbst et al., Clin. Oncol. 22, 785 (2004).
26. H. Yamazaki et al., Mol. Cell. Biol. 8, 1816, (1988).
27. M. E. Gorre et al., Science 293, 876 (2001).
28. T. J. Lynch et al., N. Engl. J. Med. 350, 2129 (2004).
29. We thank D. Altshuter, T. Golub, P. Kantoff, D. Hitt, H. Hill, Vidal, E. Lander, and D. Livingston for their advice, encouragement, and extraordinary support, and E. Lander and D. Livingston for their thoughtful comments on the manuscript. Supported by the Novartis Research Foundation, the Claudia Adams Barr Fund and the Charles A. Dana Human Cancer Genetics Program of the Dana-Farber Cancer Institute, the Poduska Family Foundation, the Gerhard Andlinger Fund, the Tisch Family Foundation, the Arthur and Linda Gelb Foundation, the Damon-Runyon Cancer Research Foundation, Joan's Legacy, the American Cancer Society, the Flight Attendant Medical Research Institute, the National Cancer Institute Lung Specialized Programs of Research Excellence and K12 programs, and numerous generous donors to the Dana-Farber Cancer Institute. M.J.E., W.R,S., and M.M. receive research funding and consulting fees from Novartis, and B.E.J. receives research funding from Eli Lilly. W.R.S. has served on the advisory board of ImClone Systems Inc. M.M. and W.R.S. have received honoraria for speaking at a meeting sponsored by AstraZeneca Pharmaceuticals. AstraZeneca is the manufacturer of gefitinib.